期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

费城染色体阳性急性淋巴细胞白血病的靶向治疗 被引量：3

原文传递
导出
摘要 急性淋巴细胞白血病 （acute lymphoblastic leukemia, ALL）是一种常合并细胞遗传学、分子生物学异常的恶性血液疾病，其中合并费城染色体（Ph）和（或）BCR/ABL（breakpoint cluster region/abelson）融合基因呈阳性的ALL，统称为Ph^＋ALL，预后极差。对其采用以酪氨酸激酶抑制剂Imatinib（伊马替尼／格列卫）为代表的靶向治疗联合化疗，目前已成为Ph^＋ALL的一线治疗，其缓解率、生存率等均优于单纯化疗，且可提高移植的疗效。
作者 秘营昌(综述)
机构地区 中国医学科学院血液病医院(血液学研究所)
出处 《国际输血及血液学杂志》 CAS 2011年第4期301-304,共4页 International Journal of Blood Transfusion and Hematology
关键词 费城染色体 BCR/ABL 急性淋巴细胞白血病(ALL) 酪氨酸激酶抑制剂 伊马替尼(imatinib)
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALI.). Blood, 2006, 108(5): 1469-1477.
  • 2Pfeifer H, Goekbuget N, Volp C, et al. Long-term outcome of 335 adult patients receiving different schedules of imatinib andchemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastie leukemia (Ph + ALl.). Blood, 2010, 116 (21) : 79a.
  • 3Thomas I)A, Kantarjian HM, Cortes JE, et al. Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALIA. Proc Am Clin Soc Oncol, 2008, 26:7019a.
  • 4de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH 2003 study. Blood, 2007, 109(4): 1408-1413.
  • 5Yanada M, Sugiura I,Takeuchi J,et al. Japan Adult Leukemia Study Group. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib combined chemotherapy. BrJ Haematol, 2008, 143(4):503-510.
  • 6Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy phased imatinib pulses improve long term outcome of adlut patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Northern Italy Leukemia Group Protocol 09/00. J Clin Oncol, 2010, 28(22) : 3644 3652.
  • 7Fielding AK, Buck G, Lazarus HM, et al. Imatinib significant enhances long-term outcomes in Philadelphia positive acute lymphoblastic lymphoblastic leukemia; Final results of the UKALL XII/ECOG 2993 trial. Blood, 2010,116(21): 77a.
  • 8Lee S, Kim YJ, Min CK, et al. The effect of first line imatinib interim therapy on the outcome of allogeneie stem cell transplantation in adults with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia. Blood, 2005, 105(9): 3449-3457.
  • 9Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietie cell transplantation for high risk Philadelphia chromosome positive leukemia. Blood, 2007, 109(7): 2791-2793.
  • 10Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as frontline treatment of elderly patients with Philadelphia chromosomepositive acute lymphoblastie leukemia (Ph+ALL). Cancer, 2007, 109(10): 2068-2076.

同被引文献62

  • 1蒋瑛,高彦荣.甲磺酸伊马替尼治疗骨髓纤维化[J].医学综述,2005,11(2):181-182. 被引量：2
  • 2马洪兵,邓承祺.伊马替尼在Ph-的慢性骨髓增殖性疾病中的应用[J].国外医学（输血及血液学分册）,2005,28(5):436-438. 被引量：1
  • 3Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative [J]. Cancer Res, 1996, 56(1): 100-104.
  • 4Druker B J, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J]. Nat Med, 1996, 2(5): 561-566.
  • 5Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP 57148B selectively inhibits the growth of BCR-ABL-positive cells [J]. Blood, 1997, 90(9): 3691- 3698.
  • 6Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J]. Blood, 1997, 90(12): 4947-4952.
  • 7Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation ofBCR/ABL+ leukemic cells and induces apoptosis [J]. Blood Cells Mol Dis, 1997, 23(3): 380-394.
  • 8Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148 [J]. Cell Death Differ, 1998, 5(8): 710-715.
  • 9Arnold K. After 30 years of laboratory work, a quick approval for STI571 [J]. J Natl Cancer Inst, 2001, 93(13): 972.
  • 10Radford IR. Imatinib. Novartis [J]. Curr Opin Investig Drugs, 2002, 3(3): 492-499.

引证文献3

二级引证文献18

国际输血及血液学杂志
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部